We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+19.23%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$140M
AUM Growth
+$21.9M
Cap. Flow
+$4.55M
Cap. Flow %
3.25%
Top 10 Hldgs %
48%
Holding
83
New
9
Increased
22
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$2.79M
2
IMMU
Immunomedics Inc
IMMU
+$2.7M
3
DERM
Dermira, Inc.
DERM
+$1.44M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.44M
5
NERV icon
Minerva Neurosciences
NERV
+$1.42M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$2.61M
2
TVRD
Tvardi Therapeutics
TVRD
+$1.75M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$747K
4
MTVA
MetaVia Inc
MTVA
+$725K
5
ABEO icon
Abeona Therapeutics
ABEO
+$338K

Sector Composition

Rank Sector Weight
1 Healthcare 92.55%
2 Miscellaneous 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$24.3M 17.37%
303,621
+2,899
+1% +$161K
ATRC icon
2
AtriCure
ATRC
$2.47B
$9.32M 6.65%
384,145
-122,801
-24% -$2.61M
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$5.63M 4.02%
637,700
+385,126
+152% +$2.7M
AERI
4
DELISTED
Aerie Pharmaceuticals
AERI
$5.61M 4%
106,770
+60,000
+128% +$2.79M
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
$5.42M 3.87%
216,119
– –
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$4.16M 2.96%
82,000
-500
-0.6% -$21.2K
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.29M 2.35%
591,128
+50,000
+9% +$305K
ONC
8
BeOne Medicines Ltd
ONC
$41.5B
$3.29M 2.35%
73,036
-8,195
-10% -$323K
PODD icon
9
Insulet
PODD
$10.1B
$3.26M 2.32%
63,484
– –
LKFT
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$2.95M 2.11%
38,609
+3,250
+9% +$273K
IBB icon
11
iShares Biotechnology ETF
IBB
$10.5B
$2.7M 1.93%
26,100
– –
ALDR
12
DELISTED
Alder Biopharmaceuticals
ALDR
$2.53M 1.81%
221,013
– –
BEAT
13
DELISTED
BioTelemetry, Inc.
BEAT
$2.51M 1.79%
75,000
– –
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.7B
$2.51M 1.79%
54,508
-4,000
-7% -$194K
NERV icon
15
Minerva Neurosciences
NERV
$231M
$2.44M 1.74%
34,540
+21,875
+173% +$1.42M
RDUS
16
DELISTED
Radius Health, Inc.
RDUS
$2.41M 1.72%
53,309
+4,500
+9% +$172K
VIRX
17
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.3M 1.64%
24,295
-492
-2% -$56.5K
DERM
18
DELISTED
Dermira, Inc.
DERM
$2.2M 1.57%
75,500
+47,500
+170% +$1.44M
AGTC
19
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.15M 1.53%
421,000
+10,000
+2% +$56.2K
SPNC
20
DELISTED
Spectranetics Corp
SPNC
$2.15M 1.53%
55,896
-9,600
-15% -$277K
MGNX icon
21
MacroGenics
MGNX
$263M
$2.09M 1.49%
119,200
– –
SGMO
22
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.98M 1.41%
+225,000
New +$1.44M
CLLS
23
Cellectis
CLLS
$342M
$1.97M 1.41%
76,404
– –
AKBA icon
24
Akebia Therapeutics
AKBA
$243M
$1.95M 1.39%
135,738
+65,283
+93% +$827K
ARDX icon
25
Ardelyx
ARDX
$984M
$1.9M 1.36%
373,409
+151,671
+68% +$1.29M
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, DAFNA Capital Management held 83 positions worth $140M, up 19% from $118M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $4.55M of net new capital in Q2 2017, opening 9 new positions and adding to 22 existing holdings. Its largest new stake was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AtriCure, an estimated $2.61M trimmed.

  • DAFNA Capital Management's largest Q2 2017 buy was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.
  • DAFNA Capital Management added most to Aerie Pharmaceuticals in Q2 2017, an estimated $2.79M increase.
  • DAFNA Capital Management's biggest Q2 2017 reduction was AtriCure, cutting an estimated $2.61M.
  • DAFNA Capital Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $1.75M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $140M portfolio in Q2 2017.
  • DAFNA Capital Management opened 9 new positions and closed 8 in Q2 2017.
  • DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $140M.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.